Cargando…
Inferring the initiation and development of myeloproliferative neoplasms
The developmental history of blood cancer begins with mutation acquisition and the resulting malignant clone expansion. The two most prevalent driver mutations found in myeloproliferative neoplasms—JAK2(V617F) and CALR(m)—occur in hematopoietic stem cells, which are highly complex to observe in vivo...
Autores principales: | Hermange, Gurvan, Rakotonirainy, Alicia, Bentriou, Mahmoud, Tisserand, Amandine, El-Khoury, Mira, Girodon, François, Marzac, Christophe, Vainchenker, William, Plo, Isabelle, Cournède, Paul-Henry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478641/ https://www.ncbi.nlm.nih.gov/pubmed/36083966 http://dx.doi.org/10.1073/pnas.2120374119 |
Ejemplares similares
-
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018) -
Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021) -
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023) -
Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms
por: Secardin, Lise, et al.
Publicado: (2021) -
HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms
por: Sevin, Margaux, et al.
Publicado: (2015)